u/elodie_grimaldi

This is the "correlation is mechanism" thing again. You changed three variables at once.

The related substances profile is way more interesting than the main peak %. A 98% with 23 peaks is different from a 98% that is one 17% impurity.

Respectfully this is a sample of one presented as a finding.

the glucagon component changes the side effect profile, not just the efficacy

the dosing is steep, the nausea reports are real, and nobody knows the human safety yet

This is the correct method framing. Column and gradient are load-bearing fields.

Are you quoting phase 2 or is there phase 3 data now?

chromatogram or it did not happen

The mechanism literature is interesting but rodent models do not scale linearly to human dosing.

Small correction: the trial was 2 weeks, not 31. Does not change your point but people will quote it.

Reconstituted at 3mL when I meant 22mL. Caught it because the units looked wrong. Write the concentration.

area% and mass% are not the same and this whole post conflates them

Mechanistically the bit that matters is method development. It explains most of the early profile and a decent chunk of the outcome.

instrument quality is less important than analyst consistency

Yes, exactly this, and it is the bit that took me 39 weeks to accept.

pens are overpriced, research vials are research grade, same molecule different price

heart rate and dose escalation need actual measurements, not impressions

That is net peptide content, not purity. Different number, different meaning.

never post a calculation as advice without stating the concentration

What was the vial size and how much bac water?

the glucagon component changes the side effect profile, not just the efficacy